Mach7 Technologies (ASX:M7T) - CEO, Mike Lampron
CEO, Mike Lampron
Source: Mach7 Technologies
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Mach7 Technologies (M7T) has secured a $7.9 million contract through its wholly-owned subsidiary with U.S. nonprofit Adventist Health System
  • Mach7 is set to roll out its full suite of picture archive communication system across 22 hospitals in the U.S., with the first round of orders expected this quarter
  • The $7.9 million arrangement includes migration services and five years of support and maintenance
  • Mach7 Chief Executive Officer Mike Lampron said he is delighted with the new collaborative partnership
  • Mach7 shares are trading 9.40 per cent higher at $1.46 each

Mach7 Technologies (M7T) has secured a $7.9 million contract through its wholly-owned subsidiary with U.S. nonprofit, Adventist Health System.

The contract amendment is for its license of the Mach7 PACS (Picture Archive Communication System), an integrated enterprise imaging solution designed to streamline hospital workflows.

The initial contract with Adventist in April 2020 included the provision of its eUnity Diagnostic Viewer and Mach7 Universal Worklist to one of the hospitals in the Adventist Health network.

Now, under the new contract, Mach7 will supply its full suite of PACS services across 22 hospitals in California, Hawaii and Oregon as part of the Adventist PACS replacement program.

The $7.9 million arrangement includes migration services and five years of support and maintenance.

According to the company, the software deployment will be implemented in stages as and when software licenses are ordered by individual hospitals in the Adventist Health group.

Mac7 expects the first round of orders for the quarter to represent roughly 7 per cent of the total contract value, as part of its longer-term goal to roll out Mach7 PACS across the majority of Adventist Health hospitals by the end of 2021.

Mach7 Chief Executive Officer Mike Lampron said he is delighted with the partnership.

“The collaborative partnership we have established with Adventist Health has allowed us to help them expand their enterprise imaging growth strategy,” he explained.

“I am confident Mach7’s full Enterprise PACS solution will provide a flexible
and scalable foundation that meets the needs of radiologists across their health
network,” he added.

Mach7 shares are trading 9.40 per cent higher at $1.46 each at 12:01 pm AEDT.

M7T by the numbers
More From The Market Online

Inoviq closes the gap on blood test results for ovarian cancer

INOVIQ has announced encouraging blood test identification results for ovarian cancer – cancer-positive tests saw a…

Paradigm Biopharma on track to US Phase III osteo program

Paradigm Biopharma has announced its completion of a submission to the US FDA to progress to…

Firebrick Pharma’s US launch of Nasal Spray is nothing to be sneezed at

Australian pharmaceutical developer, Firebrick Pharma (ASX:FRE) has launched its latest product, Nasodine Nasal Spray, in the…

AVITA Medical drops revenue forecast for Q1

AVITA Medical (ASX:AVH) provided an update on its anticipated revenue for Q1 2024 - and has…